Literature DB >> 30148403

Modeling effects of side-effect probability, side-effect severity, and medication efficacy on patients with multiple sclerosis medication choice.

David P Jarmolowicz1, Derek D Reed1, Amanda S Bruce2, Sharon Lynch3, Julia Smith4, Jared M Bruce4.   

Abstract

Multiple sclerosis (MS) is an autoimmune disease that causes a range of problematic symptoms. These symptoms tend to get worse over time, causing substantial impairment in patient quality of life. Although many effective disease-modifying therapies (DMTs) exist that slow the course of MS, patients often do not choose to take them, which may be because these medications carry substantial risks of side effects, varying from mild to severe, while only decreasing the probability of future symptoms. In the current study, we examined MS patients' self-reported likelihood of taking medications with a range of efficacies (11 values, ranging from 0.1% to 99.9%), side-effect probabilities (11 values, ranging from 0.1% to 99.9%), and side-effect severities (mild, moderate, or severe). These data were well-described by a three-dimensional probability-discounting model that isolated patients' undiscounted likelihood of taking DMTs, as well as their discounting and psychophysical scaling/weighting of side-effect probabilities and efficacy. (PsycINFO Database Record (c) 2018 APA, all rights reserved).

Entities:  

Mesh:

Year:  2018        PMID: 30148403     DOI: 10.1037/pha0000220

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  3 in total

1.  Applied Quantitative Analysis of Behavior: What It Is, and Why We Care-Introduction to the Special Section.

Authors:  David P Jarmolowicz; Brian D Greer; Peter R Killeen; Sally L Huskinson
Journal:  Perspect Behav Sci       Date:  2022-01-03

2.  Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence.

Authors:  Jared M Bruce; Amanda S Bruce; Sharon Lynch; Joanie Thelen; Seung-Lark Lim; Julia Smith; Delwyn Catley; Derek D Reed; David P Jarmolowicz
Journal:  Psychopharmacology (Berl)       Date:  2018-09-22       Impact factor: 4.530

3.  Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies.

Authors:  Hiba El Masri; Treasure M McGuire; Christine Dalais; Mieke van Driel; Helen Benham; Samantha A Hollingworth
Journal:  J Med Libr Assoc       Date:  2022-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.